Literature DB >> 15918194

Inhibition of PMA-induced endothelial cell activation and adhesion by over-expression of domain negative IkappaBalpha protein.

Jian-Feng Wei1, Ke Sun, Shi-Guo Xu, Hai-Yang Xie, Shu-Sen Zheng.   

Abstract

AIM: NF-kappaB, regulate the expression of cytokine-inducible genes involving immune and inflammatory responses, will be potential therapy approach for allograft from rejection. In this study, we use pCMV- IkappaBalphaM vector to inhibit NF-kappaB activation and investigate the effect of pCMV- IkappaBalphaM in inhibition of T cells adhesion to endothelial cells.
METHODS: The NF-kappaB activity was detected with pNF-kappaB reporter gene and electrophoretic mobility shift assay. Expression of cell surface molecules was detected by RT-PCR and flow cytometer. The cell-cell adhesion assay was performed to determine the effect of pCMV-IkappaBalphaM in inhibition of T cells adhesion to endothelial cells.
RESULTS: We could find that NF-kappaB activity is inhibited by over-expression of non-degraded IkappaBalpha protein. Expression of adhesion molecules like ICAM-1, VCAM-1, and P-selectin as well as cell-cell adhesion were inhibited significantly by transfection of the pCMV- IkappaBalphaM vector.
CONCLUSION: Our results indicate that the pCMV- IkappaBalphaM, which inhibit the activity of NF-kappaB through over-expression of non-degraded IkappaBalpha protein, can be used for gene therapy in diseases involving NF-kappaB activation abnormally like organ transplantation via inhibiting cell adhesion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15918194      PMCID: PMC4305844          DOI: 10.3748/wjg.v11.i20.3080

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

Review 1.  Chemokines: directing leukocyte infiltration into allografts.

Authors:  Tarek el-Sawy; Nader M Fahmy; Robert L Fairchild
Journal:  Curr Opin Immunol       Date:  2002-10       Impact factor: 7.486

Review 2.  Application of antisense oligodeoxynucleotides for organ transplantation.

Authors:  S M Stepkowski
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

Review 3.  Endothelial-leukocyte adhesion molecules.

Authors:  M P Bevilacqua
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 4.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Ex vivo gene therapy prevents chronic graft vascular disease in cardiac allografts.

Authors:  R S Poston; M Ennen; J Pollard; E G Hoyt; M E Billingham; R C Robbins
Journal:  J Thorac Cardiovasc Surg       Date:  1998-09       Impact factor: 5.209

6.  Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts.

Authors:  J Suzuki; R Morishita; J Amano; Y Kaneda; M Isobe
Journal:  Gene Ther       Date:  2000-11       Impact factor: 5.250

Review 7.  The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection.

Authors:  M D Denton; S F Davis; M A Baum; M Melter; M E Reinders; A Exeni; D V Samsonov; J Fang; P Ganz; D M Briscoe
Journal:  Pediatr Transplant       Date:  2000-11

Review 8.  Anoxia/reoxygenation-induced leukocyte-endothelial cell interactions.

Authors:  Satoshi Kokura; Norimasa Yoshida; Toshikazu Yoshikawa
Journal:  Free Radic Biol Med       Date:  2002-08-15       Impact factor: 7.376

9.  Methemoglobin is a potent activator of endothelial cells by stimulating IL-6 and IL-8 production and E-selectin membrane expression.

Authors:  Xueying Liu; Zoltán Spolarics
Journal:  Am J Physiol Cell Physiol       Date:  2003-07-02       Impact factor: 4.249

10.  Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.

Authors:  B Frantz; E C Nordby; G Bren; N Steffan; C V Paya; R L Kincaid; M J Tocci; S J O'Keefe; E A O'Neill
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.